Patología vascular: ¿causa o efecto en la enfermedad de Alzheimer?
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Resumen Introducción La enfermedad de Alzheimer (EA) es la principal enfermedad neurodegenerativa cortical. Su incidencia aumenta con la edad, lo que provoca importantes problemas médicos, sociales y económicos, especialmente en países con población envejecida. Objetivo El objetivo de esta revisión es poner de manifiesto las evidencias que existen sobre el modo en que la disfunción vascular puede contribuir al deterioro cognitivo en la EA, así como las posibilidades terapéuticas que de ello podrían derivarse. Desarrollo La hipótesis vascular ha surgido como alternativa a la hipótesis de la cascada amiloide como explicación de la fisiopatología de la EA. Esta hipótesis sitúa en los vasos sanguíneos el origen de una serie de estímulos patogénicos que llevarían a la lesión neuronal y la demencia. La destrucción de la organización de la barrera hematoencefálica, la disminución del flujo sanguíneo cerebral y el establecimiento de un contexto inflamatorio serían responsables de un consecuente daño neuronal a causa de favorecer la agregación del péptido β-amiloide en el cerebro. Las vías que relacionan la disfunción vascular con la neurodegeneración han proporcionado nuevos enfoques terapéuticos y dianas farmacológicas con las que avanzar en la búsqueda de tratamientos para la EA. Conclusiones Resulta difícil determinar si el componente vascular de la EA es la causa o el efecto de la enfermedad, pero no cabe duda de que la enfermedad vascular tiene una relación importante con la EA. Es probable que la disfunción vascular actúe sinérgicamente con los cambios neurodegenerativos en un ciclo que agrava el deterioro cognitivo propio de la EA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“…hematoencefá-lica (BHE), en el suministro de nutrientes, en la degradación eficiente de moléculas tóxicas, en las funciones enzimáticas, en la secreción de factores tróficos y moléculas de la matriz, en la expresión de receptores vasculares o en la inducción de la secreción de ectoenzimas 40 .”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“Por otra parte, en 1995 se había observado que las mutacio-nes autosómicas dominantes en el gen de la presenilina-1 (PTEN-1) y presenilina-2 (PTEN-2) presentes en el cromo-soma 14 y 1, respectivamente, podían causar la EA 16,17 .”
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“La hipótesis de la cascada amiloide se˜nala, por tanto, neurodegenerativo y a la demencia 19 20 procesamiento de la APP puede ocurrir por 2 vías: bien por una vía no amiloidogénica o bien por una vía amiloidogénica (fig.”
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 1×
“Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 2×
“Sin embargo, no existía evidencia que indicase que estos fár-macos eran capaces de reparar las neuronas da˜nadas o de degradar las placas seniles ya existentes 76,77 Es posible que los ensayos clínicos se hayan realizado en un momento en el que ya se había perdido la oportunidad terapéutica, intervi-niendo demasiado t…”
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“…de LRP1 en los microvasos cerebrales están asociados con la acumulación del A (cid:2) en el cerebro durante el envejeci-miento y durante la EA 47,48 Se ha demostrado también que el LRP1 cerebral se oxida en la EA mediante un mecanismo oxidativo que puede implicar al propio A (cid:2) , lo que…”
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771
Alzheimer neuropathologic alterations in aged cognitively normal subjects
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199904000-00008 · Cited by 516 · cited 1×
“…aguda al da˜no neuronal 29 Además, el grado de deposición del péptido A (cid:2) no se ha podido corre-lacionar con la gravedad de la disfunción cognitiva en los pacientes con EA, e incluso se han hallado deposiciones amiloides en cerebros de muchos individuos con funciones cognitivas normales 30”
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440 · cited 1×
“Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H., & Zhang, Y.-W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608856200 · Cited by 436
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432
Liu, Q., Zerbinatti, C. V., Zhang, J., Hoe, H.-S., Wang, B., Cole, S. L., Herz, J., Muglia, L., & Bu, G. (2007) · Neuron · doi:10.1016/j.neuron.2007.08.008 · Cited by 364
Clearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Type 2 diabetes mellitus and Alzheimer’s disease
Barbagallo, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.889 · Cited by 313
Risk Factors for β-Amyloid Deposition in Healthy Aging: Vascular and Genetic Effects
Rodrigue, K. M., Rieck, J. R., Kennedy, K. M., Devous, M. D., Diaz-Arrastia, R., & Park, D. C. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1342 · Cited by 249
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000128091.92139.0f · Cited by 226 · cited 1×
“Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
From Chronic Cerebral Hypoperfusion to Alzheimer-Like Brain Pathology and Neurodegeneration
Zhao, Y., & Gong, C.-X. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0127-9 · Cited by 180
Choi, B.-R., Cho, W.-H., Kim, J., Lee, H. J., Chung, C., Jeon, W. K., & Han, J.-S. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.147 · Cited by 111
Chronic cerebral hypoperfusion accelerates amyloid β deposition in APPSwInd transgenic mice
Kitaguchi, H., Tomimoto, H., Ihara, M., Shibata, M., Uemura, K., Kalaria, R. N., Kihara, T., Asada-Utsugi, M., Kinoshita, A., & Takahashi, R. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.078 · Cited by 108
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Research works printed but not linked: 45
- Ferri, 2005, Global prevalence of dementia: A Delphi consensus study, Lancet., 366, 2112, 10.1016/S0140-6736(05)67889-0 · DOI · Paper page
- Gascon-Bayarri, 2007, Prevalence of dementia subtypes in el Prat de Llobregat, Catalonia, Spain: the PRATICON study, Neuroepidemiology., 28, 224, 10.1159/000108597 · DOI · Paper page
- Maurer, 1997, Auguste D and Alzheimer's disease, Lancet., 349, 1546, 10.1016/S0140-6736(96)10203-8 · DOI · Paper page
- Glenner, 1984, Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun., 120, 885, 10.1016/S0006-291X(84)80190-4 · DOI · Paper page
- Goldgaber, 1987, Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease, Science., 235, 877, 10.1126/science.3810169 · DOI · Paper page
- Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature., 349, 704, 10.1038/349704a0 · DOI · Paper page
- Hardy, 1992, Alzheimer's disease: The amyloid cascade hypothesis, Science., 256, 184, 10.1126/science.1566067 · DOI · Paper page
- Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science., 297, 353, 10.1126/science.1072994 · DOI · Paper page
- Vassar, 1999, Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science., 286, 735, 10.1126/science.286.5440.735 · DOI · Paper page
- Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature., 375, 754, 10.1038/375754a0 · DOI · Paper page
- Wolfe, 1999, Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity, Nature., 398, 513, 10.1038/19077 · DOI · Paper page
- Bergmans, 2010, Gamma-secretases. From cell biology to therapeutic strategies, Lancet Neurol., 9, 215, 10.1016/S1474-4422(09)70332-1 · DOI · Paper page
- Alonso Vilatela, 2012, Genetics of Alzheimer's disease, Arch Med Res., 43, 622, 10.1016/j.arcmed.2012.10.017 · DOI
- Grundke-Iqbal, 1986, Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, J Biol Chem., 261, 6084, 10.1016/S0021-9258(17)38495-8 · DOI · Paper page
- De la Torre, 1993, Can disturbed brain microcirculation cause Alzheimer's disease?, Neurol Res., 15, 146, 10.1080/01616412.1993.11740127 · DOI · Paper page
- Gentleman, 1993, Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury, Neurosci Lett., 160, 139, 10.1016/0304-3940(93)90398-5 · DOI · Paper page
- Xu, 2011, Midlife overweight and obesity increase late-life dementia risk: A population-based twin study, Neurology., 76, 1568, 10.1212/WNL.0b013e3182190d09 · DOI · Paper page
- Domínguez, 2014, Enfermedad de Alzheimer y deterioro cognitivo asociado a la diabetes mellitus de tipo 2: relaciones e hipótesis, Neurologia., 29, 567, 10.1016/j.nrl.2013.05.006 · DOI
- Kopf, 2009, Risk of incident Alzheimer's disease in diabetic patients: A systematic review of prospective trials, J Alzheimers Dis., 16, 677, 10.3233/JAD-2009-1011 · DOI · Paper page
- Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study, Lancet., 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
- Mooradian, 1997, GLUT-1 expression in the cerebra of patients with Alzheimer's disease, Neurobiol Aging., 18, 469, 10.1016/S0197-4580(97)00111-5 · DOI · Paper page
- Sagare, 2012, Low-density lipoprotein receptor-related protein 1: A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities, Pharmacol Ther., 136, 94, 10.1016/j.pharmthera.2012.07.008 · DOI · Paper page
- Owen, 2010, Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Aβ accumulation in AD brain, Free Radic Biol Med., 49, 1798, 10.1016/j.freeradbiomed.2010.09.013 · DOI · Paper page
- Johnson, 2000, Perfusion abnormalities in prodromal AD, Neurobiol Aging., 21, 289, 10.1016/S0197-4580(00)00137-8 · DOI
- De la Torre, 2002, Vascular basis of Alzheimer's pathogenesis, Ann N Y Acad Sci., 977, 196, 10.1111/j.1749-6632.2002.tb04817.x · DOI · Paper page
- Zlokovic, 2005, Neurovascular mechanisms of Alzheimer's neurodegeneration, Trends Neurosci., 28, 202, 10.1016/j.tins.2005.02.001 · DOI · Paper page
- Marshall, 2006, Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels, Brain Res., 1099, 18, 10.1016/j.brainres.2006.05.008 · DOI
- Kelleher, 2013, Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?, Am J Cardiovasc Dis., 3, 197
- Wakita, 1992, Regional accumulation of amyloid beta/A4 protein precursor in the gerbil brain following transient cerebral ischemia, Neurosci Lett., 146, 135, 10.1016/0304-3940(92)90061-B · DOI
- Austin, 2010, Endothelial nitric oxide modulates expression and processing of amyloid precursor protein, Circ Res., 107, 1498, 10.1161/CIRCRESAHA.110.233080 · DOI · Paper page
- Zhao, 2011, The contribution of activated astrocytes to Abeta production: Implications for Alzheimer's disease pathogenesis, J Neuroinflammation., 8, 150, 10.1186/1742-2094-8-150 · DOI · Paper page
- Li, 2009, Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier, J Immunol., 182, 5778, 10.4049/jimmunol.0803013 · DOI · Paper page
- Galimberti, 2011, Disease-modifying treatments for Alzheimer's disease, Ther Adv Neurol Disord., 4, 203, 10.1177/1756285611404470 · DOI · Paper page
- Hayden, 2007, Does NSAID use modify cognitive trajectories in the elderly? The Cache County study, Neurology., 69, 275, 10.1212/01.wnl.0000265223.25679.2a · DOI · Paper page
- Pasinetti, 2002, From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: The role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia, J Alzheimers Dis., 4, 435, 10.3233/JAD-2002-4510 · DOI · Paper page
- Simons, 2002, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial, Ann Neurol., 52, 346, 10.1002/ana.10292 · DOI · Paper page
- Sano, 2011, A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease, Neurology., 77, 556, 10.1212/WNL.0b013e318228bf11 · DOI · Paper page
- Shinohara, 2010, Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance, J Biol Chem., 285, 22091, 10.1074/jbc.M110.102277 · DOI · Paper page
- Li, 2006, Simvastatin enhances learning and memory independent of amyloid load in mice, Ann Neurol., 60, 729, 10.1002/ana.21053 · DOI · Paper page
- Wanamaker, 2015, Cholesterol, statins, and dementia: What the cardiologist should know, Clin Cardiol., 38, 243, 10.1002/clc.22361 · DOI · Paper page
- Yasar, 2013, Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo evaluation of memory study, Neurology., 81, 896, 10.1212/WNL.0b013e3182a35228 · DOI · Paper page
- Ashby, 2013, Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease, Expert Opin Investig Drugs., 22, 1229, 10.1517/13543784.2013.812631 · DOI · Paper page
- Zlokovic, 2008, New therapeutic targets in the neurovascular pathway in Alzheimer's disease, Neurotherapeutics., 5, 409, 10.1016/j.nurt.2008.05.011 · DOI · Paper page
- Hong-Qi, 2012, Current advances in the treatment of Alzheimer's disease: Focused on considerations targeting Aβ and tau, Transl Neurodegener., 1, 21, 10.1186/2047-9158-1-21 · DOI
- Galasko, 2014, Clinical trial of an inhibitor of RAGE-abeta interactions in Alzheimer disease, Neurology., 82, 1536, 10.1212/WNL.0000000000000364 · DOI · Paper page
Cited by
Glymphatic failure as a final common pathway to dementia
Nedergaard, M., & Goldman, S. A. (2020) · Science · doi:10.1126/science.abb8739 · Cited by 1,145
The multiplex model of the genetics of Alzheimer's disease
Sims, R., Hill, M., & Williams, J. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0599-5 · Cited by 466
Daulatzai, M. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 429
Getting to the Heart of Alzheimer Disease
Tublin, J. M., Adelstein, J. M., del Monte, F., Combs, C. K., & Wold, L. E. (2019) · Circulation Research · doi:10.1161/circresaha.118.313563 · Cited by 188
mTOR signaling and Alzheimer's disease: What we know and where we are?
Davoody, S., Asgari Taei, A., Khodabakhsh, P., & Dargahi, L. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14463 · Cited by 96
Metadata
- Authors
- Rius-Pérez, S., Tormos, A. M., Pérez, S., & Taléns-Visconti, R.
- Venue
- Neurología
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 33
- Issue
- 2
- Pages
- 112-120
- ISSN
- 0213-4853 (ISSN-L)
- OpenAlex
- W2588435967
- Cited by
- 70
- References
- 37
- FWCI
- 1.51
- Type
- journal article
- Language
- es
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.